CCR2 and familial pancreatic carcinoma: Another combination therapy, investigated in ongoing Phase Ib/II clinical trials, consists in the use of a dual CCR2/CCR5 antagonist plus chemotherapy or nivolumab in patients with metastatic colorectal and pancreatic cancer.